Khiron Life Sciences closes overnight brokered offering including full exercise of over-allotment option

1 minute read
10 June 2022

On June 10, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) closed its previously announced underwritten overnight public offering of units of the company, including the exercise in full of the over-allotment option.

A total of 30,705,000 units were sold for aggregate gross proceeds of $4,605,750. The offering was completed by a syndicate of underwriters led by Canaccord Genuity Corp., including ATB Capital Markets Inc. and Leede Jones Gable Inc.

Khiron is a leading vertically integrated international medical cannabis corporation with core operations in Latin America and Europe. The company has a sales presence in Colombia, Peru, Germany, the United Kingdom and Brazil and is positioned to commence sales in Mexico.

Gowling WLG was counsel to Khiron in this transaction with a team that included Peter Simeon, Jacob Cawker and Ashley Andaya.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.